489 related articles for article (PubMed ID: 25596769)
21. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.
van Ryn J; Schurer J; Kink-Eiband M; Clemens A
Anesthesiology; 2014 Jun; 120(6):1429-40. PubMed ID: 24714118
[TBL] [Abstract][Full Text] [Related]
22. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
23. Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.
Percy CL; Hartmann R; Jones RM; Balachandran S; Mehta D; Dockal M; Scheiflinger F; O'Donnell VB; Hall JE; Collins PW
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):357-67. PubMed ID: 25928274
[TBL] [Abstract][Full Text] [Related]
24. Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts.
Larsen OH; Stentoft J; Radia D; Ingerslev J; Sørensen B
Br J Haematol; 2013 Jan; 160(2):228-36. PubMed ID: 23151086
[TBL] [Abstract][Full Text] [Related]
25. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
[TBL] [Abstract][Full Text] [Related]
26. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
[TBL] [Abstract][Full Text] [Related]
27. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
[TBL] [Abstract][Full Text] [Related]
28. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
[TBL] [Abstract][Full Text] [Related]
29. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
30. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
33. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
34. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Takeshita S; Ogawa S; Nakayama Y; Mukai N; Nakajima Y; Mizobe T; Sawa T; Tanaka KA
Anesth Analg; 2019 Aug; 129(2):339-345. PubMed ID: 30320649
[TBL] [Abstract][Full Text] [Related]
35. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
[TBL] [Abstract][Full Text] [Related]
37. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
[TBL] [Abstract][Full Text] [Related]
38. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
[TBL] [Abstract][Full Text] [Related]
39. Rational and timely haemostatic interventions following cardiac surgery - coagulation factor concentrates or blood bank products.
Tang M; Fenger-Eriksen C; Wierup P; Greisen J; Ingerslev J; Hjortdal V; Sørensen B
Thromb Res; 2017 Jun; 154():73-79. PubMed ID: 28437748
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Solbeck S; Meyer MA; Johansson PI; Meyer AS; Cotton BA; Stensballe J; Schött U; Ostrowski SR
Int J Cardiol; 2014 Oct; 176(3):794-9. PubMed ID: 25156858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
